摘要
针对急性心肌梗死(AMI)并发泵衰竭患者药物治疗不佳的难点,使用国产新型钙增敏剂左西孟旦治疗,观察药物治疗的临床有效率、心衰恶化或死亡率、超声心动图(UCG)左室射血分数(LVEF)及氨基末端脑钠肽前体(NT-ProBNP)、高敏C-反应蛋白(hs-CRP)的变化,结果表明国产左西孟旦治疗急性心肌梗死合并泵衰竭疗效确切,安全性及患者耐受性良好.
Due to the poor efficacy of routine drug therapy in patients with pump failure due to an acute myocar-dial infarction,a domestic new calcium sensitizer levosimendan treatment is researched in this paper. The chan-ges in the clinical effective rate,ultrasonic cardiogram (UCG)and amino terminal brain natriuretic peptide pre-cursor (NT-ProBNP),allergic C -reactive protein (hs -CRP)are then observed. The results show that do-mestic levosimendan has definite therapeutic effect on acute myocardial infarction with pump failure,which is safe and well tolerated in patients.
出处
《昆明理工大学学报(自然科学版)》
CAS
北大核心
2014年第2期74-78,共5页
Journal of Kunming University of Science and Technology(Natural Science)
基金
国家自然科学基金项目(31301456)
关键词
左西孟旦
急性心肌梗死
泵衰竭
疗效
levosimendan
acute myocardial infarction
pump failure
efficacy